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Creams are heterogenous biphasic semi-solid preparations consisting of oil and aqueous phases, 
wherein one phase is dispersed in the other and stabilized using a suitable emulsifier. The active 
pharmaceutical ingredient is either dissolved or dispersed in continuous or dispersed phase of the 
formulation. Water is the most common and the major constituent in the preparation of creams. 
However, certain moisture sensitive drugs like mechlorethamine, acyclovir, itraconazole and 
ketoconazole are liable to degradation in presence of water thereby decreasing the stability of the 
formulation. Hence, there is a need for formulation suitable for incorporating water sensitive drugs. 
Creams prepared with polyethylene glycol instead of water could be an alternative to creams 
prepared using water to improve the stability of the drug. Moreover, PEGs are generally used as 
drug penetration enhancers and solubilizers in cream preparations. The objective of present study 
was to develop and optimize Oil in PEG creams suitable for incorporating moisture sensitive drugs 
and to investigate the feasibility of twin-screw processor in the continuous manufacturing of 
topical semi-solid cream formulation. 
Voriconazole (VRC) was selected as a model drug for preparation of Oil/PEG cream consisting of 
PEG 2000, PEG 400 and propylene glycol after performing drug-excipient compatibility studies. 
Twin screw processor with a 10 mm co-rotating twin screw configuration was used for preparation 
of oil/PEG creams. Creams prepared using twin-screw processor were characterized for the 
following: Differential Scanning Calorimetry (DSC), pH, Solvent activity (as)), viscosity, drug 
content uniformity, in vitro drug release testing (IVRT) and in vitro permeation testing (IVPT) 
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VRC   Voriconazole 
PEG   Polyethylene Glycol 
PG   Propylene glycol 
ACN    Acetonitrile 
PBS   Phosphate buffer solution/saline 
HME   Hot Melt Extrusion  
HPLC   High pressure/performance liquid chromatography 
UV/VIS  Ultraviolet/Visible spectroscopic detection 
FT-IR   Fourier Transform Infrared Spectroscopy  
DSC   Differential Scanning Microscopy  
RPM   Rotations/revolutions/rate per minute 
FDC   Franz-Diffusion cells 
IV-RT   in-vitro release testing 
IV-PT                          in-vitro permeation testing 
SC                               Subcutaneous 
API   Active pharmaceutical ingredient 
O/W or W/O               Oil in Water or Water in Oil 
O/PEG                         Oil in Polyethylene glycol  
DMSO                         Dimethyl Sulfoxide 
aw                                            Solvent activity 
AUC                            Area under the curve 
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CHAPTER I: INTRODUCTION 
 
Creams are heterogenous semi-solid preparations, where oil in water (O/W) or water in oil (W/O) 
is dispersed and stabilized using a suitable emulsifier. O/W creams are most commonly used 
topical formulation for various dermatological disorders. Moisture sensitive drugs like 
mechlorethamine, acyclovir, itraconazole and ketoconazole are liable to degradation in water 
phase. Hence, there is a need for developing cream formulation using non-aqueous hydrophilic 
component. Polyethylene glycol (PEG) is a polyether compound which is produced by the 
interaction of ethylene oxide with ethylene glycols and water. PEG has many applications, from 
industrial manufacturing to medicine. PEG is also used as an excipient in many pharmaceutical 
products. PEG is a product of condensed ethylene oxide and hydrophilic in nature.  Moreover, 
PEGs are generally used as drug penetration enhancers and solubilizers in cream preparation. In 
the current study, PEG was used in preparation of creams instead of water, in order to overcome 
the degradation of moisture sensitive drugs [1][2].  
Advantages of preparation of creams using twin-screw processor over homogenization 
 
Creams are prepared by homogenization of the ingredients which involves applying sufficient 
energy to disperse one phase into another [1]. However, homogenization method for preparation of 
creams has several disadvantages; 1. Homogenization is a multistep process, hence time and 
resources invested in each batch is more resulting in lesser productivity and efficiency, 2. 
Homogenization is a batch process; hence variations are observed between batch to batch process. 
In this project, we investigated the application of hot melt extrusion (HME) technology in 
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preparation of topical semi-solid creams for continuous manufacturing of a topical semi-solid 
cream formulation. HME provides many advantages over conventional method like 
homogenization technique for preparation of creams, such as reduced processing time as it is 
continuous process or one-step process. Moreover, the variations involved in preparation of creams 
using twin screw extruder are less compared to homogenization technique. Moreover, no 
additional agitators and scrapers are required since mixing action is performed by the screw 
elements in the barrel. The screw elements also aid in particle size reduction. Additionally, the 
processing parameters could be customized to obtain products with desired characteristics [3] with 
the high yield and minimum material loss. 
Active Pharmaceutical Ingredient 
 
In this project, voriconazole (Fig. 1) an antifungal drug was selected for the study. Voriconazole 
has a tendency to undergo neutral hydrolytic conditions, hence this project was designed to 
incorporate voriconazole in oil/PEG creams [31][38][39]. Voriconazole is a triazole antifungal 
medication used to treat serious fungal infections. It is used to treat invasive fungal infections that 
are generally seen in patients who are immunocompromised. These include invasive candidiasis, 
invasive aspergillosis, and emerging fungal infections caused by Scedosporium 
apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium 
solani. Fungal plasma membranes are similar to mammalian plasma membranes, differing in 
having the nonpolar sterol ergosterol, rather than cholesterol, as the principal sterol. Membrane 
sterols such as ergosterol provide structure, modulation of membrane fluidity, and possibly control 
of some physiologic events. Voriconazole effects the formation of the fungal plasma membrane 
by indirectly inhibiting the biosynthesis of ergosterol. This results in plasma membrane 





 Mechanism of action: Voriconazole binds and inhibits ergosterol synthesis by inhibiting CYP450-
dependent 14-alpha sterol demethylase. The inhibition of 14-alpha sterol demethylase results in a 
depletion of ergosterol in fungal cell membrane.  
 
Physicochemical properties of voriconazole:  
The melting point of voriconazole was found to be 127-130 ºC, log P value was 1, and voriconazole 
do not show any degradation at dry heat 70 ºC [37]. Voriconazole is soluble in solvents like 
propylene glycol. 
 
Figure 1. Structure of voriconazole 
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CHAPTER II: MATERIALS AND METHODS 
Materials 
 
PEG 4500 and light mineral oil were purchased from PCCA (Houston, TX), PEG 2000 was 
purchased from Sigma-Aldrich, now Millipore Sigma (Darmstadt, Germany), PEG 400 was 
purchased from BASF (New Jersey, USA), Labrafil M1944 CS, Tefose 63 and Transcutol P were 
kindly gifted by Gattefosse (Saint Priest, France), Menthol and Camphor were purchased from 
Ward’s Science (Rochester, New York, USA) and Voriconazole (Batch no. RVK6H-QO) was 
purchased from VWR (New Jersey, USA),  All other chemicals and solvents (Methanol and 
Acetonitrile) used were of HPLC grade. DI water was used in all studies and obtained from a 
MilliQ water filtration unit. 
Methods 
 
Screening of the Excipients 
 
Before formulation development, it is important to screen the excipients in order to develop a 
stable formulation.  Initial strategy included screening of the excipients for the base formulation. 
Screening of the excipients was done by FTIR studies to identify any chemical interactions.   
Fourier Transform Infrared Spectroscopy (FT-IR) 
Understanding of physicochemical interactions of an active pharmaceutical ingredient (API) and 
pharmaceutically inactive ingredients (excipients) in the dosage forms is an integral part of pre-
formulation studies, to develop a new dosage form. Although excipients are pharmacologically 
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inert, they can interact with drugs in the dosage form to affect drug product stability, hence drug 
excipient compatibility studies were performed to study the interactions [5]. Voriconazole and 
excipients were analyzed using Cary 600 series Fourier transform infrared spectrometer, Agilent 
Technologies (FT-IR). 
Preparation and optimization of Oil/PEG cream 
Oil/PEG creams were prepared by varying different grades of PEGs in combination with propylene 
glycol as aqueous phase. The Oil/PEG creams F1 through F32 (table 1) was prepared by keeping 
a constant amount of Voriconazole, propylene glycol, Labrafil M 1944 CS, light mineral oil, and 
Tefose 63; and by varying the amount of high molecular weight/solid PEGs (PEG 4500, PEG 
3350, PEG 2000,  and PEG 1450 and low molecular weight/liquid PEG (PEG 400). The Oil/PEG 
creams were prepared by adding the oil phase containing Tefose 63 (emulsifier) to the hydrophilic 
phase at 70 °C by employing high shear homogenization technique. Labrafil M 1944 CS was used 
in the oil phase because it is an excellent water dispersible surfactant, solubilizer and 
bioavailability enhancer. Labrafil M 1944 CS is often used as co-emulsifier in topical formulations 
along with Tefose 63 in antifungal creams [32]. The prepared creams were subjected to freeze thaw 
stability studies, where the creams were exposed to 3 cycles of freeze and thaw and evaluated 
visually for the phase separation of the formulation. Creams which did not undergo phase 




Table 1. Composition of formulations used to screen Oil/PEG creams 
Formulation Proportion of PEGs Oil Phase 
F1 PEG 1450: PEG 400 (15:85) Labrafil M1944 CS 
F2 PEG 1450: PEG 400 (15:85) Light mineral oil 
F3 PEG 1450: PEG 400 (20:80) Labrafil M1944 CS 
F4 PEG 1450: PEG 400 (20:80) Light mineral oil 
F5 PEG 1450: PEG 400 (30:70) Labrafil M1944 CS 
F6 PEG 1450: PEG 400 (30:70) Light mineral oil 
F7 PEG 1450: PEG 400 (50:50) Labrafil M1944 CS 
F8 PEG 1450: PEG 400 (50:50) Light mineral oil 
F9 PEG 2000: PEG 400 (15:85) Labrafil M1944 CS 
F10 PEG 2000: PEG 400 (15:85) Light mineral oil 
F11 PEG 2000: PEG 400 (20:80) Labrafil M1944 CS 
F12 PEG 2000: PEG 400 (20:80) Light mineral oil 
F13 PEG 2000: PEG 400 (30:70) Labrafil M1944 CS 
F14 PEG 2000: PEG 400 (30:70) Light mineral oil 
F15 PEG 2000: PEG 400 (50:50) Labrafil M1944 CS 
F16 PEG 2000: PEG 400 (50:50) Light mineral oil 
F17 PEG 3350: PEG 400 (15:85) Labrafil M1944 CS 
F18 PEG 3350: PEG 400 (15:85) Light mineral oil 
F19 PEG 3350: PEG 400 (20:80) Labrafil M1944 CS 
F20 PEG 3350: PEG 400 (20:80) Light mineral oil 
F21 PEG 3350: PEG 400 (30:70) Labrafil M1944 CS 
F22 PEG 3350: PEG 400 (30:70) Light mineral oil 
F23 PEG 3350: PEG 400 (50:50) Labrafil M1944 CS 
F24 PEG 3350: PEG 400 (50:50) Light mineral oil 
F25 PEG 4500: PEG 400 (15:85) Labrafil M1944 CS 
F26 PEG 4500: PEG 400 (15:85) Light mineral oil 
F27 PEG 4500: PEG 400 (20:80) Labrafil M1944 CS 
F28 PEG 4500: PEG 400 (20:80) Light mineral oil 
F29 PEG 4500: PEG 400 (30:70) Labrafil M1944 CS 
F30 PEG 4500: PEG 400 (30:70) Light mineral oil 
F31 PEG 4500: PEG 400 (50:50) Labrafil M1944 CS 
F32 PEG 4500: PEG 400 (50:50) Light mineral oil 
 
Preparation of selected formulation using Twin screw processor 
 
Hot melt extrusion method 
 
Creams were prepared by co-rotating twin screw extruder (OMICRON 10, STEER Life) (Fig. 2). 
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For this method all the ingredients of aqueous phase and oil phase were weighed accurately and 
the mixture was heated on a hot plate maintained at a temperature of 70±5ºC.  
 
Figure 2. Omicron 10 [Mini] with Do/Di ratio 1.71 for manufacturing of the Cream formulation. 
Based on the optimization of the screw with diameter ratio (Do/Di) 1.71 was selected for the 
extrusion process. Processing parameters for twin screw processor are described in Table 2. Screw 
speed was set to 200 RPM. Feeder speed was set to 30 rpm to feed the material at 1.8 g/min, and 
0.595 - 1.19 mm particle size of PEG 2000 were used. Optimization of the peristaltic pump was 
done to give proper feed at feeding zone and zone 2. For the optimization of the peristaltic pump 
weight of material dispensed per minute vs RPM of the peristaltic pump was noted. A peristaltic 
pump set to a flow rate of 45 RPM was used to dispense the aqueous phase at the feeding zone and 
peristaltic pump set to a flow rate of pump 20 RPM was used to dispense the oil phase at the zone 
2.  After the optimization of both peristaltic pumps, the aqueous phase containing a 15:85 mixture 
of PEG 2000 and PEG 400 was passed through the feeding zone. The peristaltic pump dispensing 
the aqueous phase was set to an RPM of 45. The oil phase was introduced at zone 2 for proper 
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mixing with the aqueous phase. A peristaltic pump dispensing the oil phase was set to an RPM of 
20. The RPM was adjusted according to the percentage of composition in aqueous phase (75%) 
and oil phase (25%) as needed. At the end zone (collecting zone) creams which were prepared 
were collected in a container and allowed to cool down to room temperature.  The creams were 
then refrigerated for further study. 
Table 2. Processing parameters for the manufacturing of creams by Hot melt extrusion. 
PARAMETERS DESCRIPTION 
Equipment OMICRON 10 with Do/Di ratio 1.71, STEER Life 
Screw design Co-rotating twin screw extruder 
Barrel Diameter 10 mm 
Barrel temperature 
Zone 1 - 70 ℃ 
Zone 2 - 40 ℃ 
RPM 200 
Torque 0-3 Nm/Shaft 
 
Characterization of Oil/PEG creams: 
 
Differential Scanning Calorimetry (DSC) Analysis 
 
DSC was performed to analyze the glass transition temperature and melting point of pure 
ingredients and selected cream formulations. Thermograms were obtained using TA Instruments 
Discovery Series DSC 25, New Castle, DE, USA. Analysis was performed over the temperature 
range of 20°C to 200°C at 10°C increments.  The nitrogen purge was set at 20°C/min. Samples 
were weighed accurately (around 5 mg) in an aluminum pan, sealed with a hermetic lid. TRIOS 
software was used as a means to analyze the solid-state characteristics and thermal stability of the 
voriconazole, excipients and the formulations. 
pH measurement 
 
         The pH of the creams was measured by using Mettler Toledo InLab®Micro pH probe (Electrolyte 
3 mol/L KCl). The pH meter was calibrated using standard buffers with the known pH of 4.0, 7.0 
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and 10.0 respectively. The pH of each cream formulation was measured in triplicate (n=3). In 
between every individual measurement, pH reading of the standard buffer pH 4.0 was taken 
followed by next reading and a standard buffer of pH 10.0 respectively. 
Solvent Activity (aW) measurements  
The solvent activity of all cream formulations was measured by using AQUALAB water activity 









Figure 3. Water activity meter (Series 3E, USA) 
 
Initially the instrument was calibrated using standards. A whole vial of solution was transferred 
into a sample cup and was placed in the Aqualab’s sample drawer. Two readings were taken to get 
the aw within ± 0.003 of the given value. Distilled water was then placed in the drawer and the 
reading was noted, to ensure that it is within 1.000 ± 0.003. The instrument was found to be suitable 
when the water activity for DI water was equal to 1.00. Once the calibration was done, activated 
charcoal cup was kept in the drawer and the knob was turned on, in order to remove any moisture 
present before running the samples. The values were noted in triplicate (n=3). In between each 
reading activated charcoal was placed in the chamber to remove moisture. The samples were 




The viscosity of the prepared formulations was determined using a Brookfield viscometer (DV-
II+). The temperature maintained for the study was 21°C. The spindle (3.2 cm) RPM was set to 
0.3. The instrument was allowed to stabilize for 15 minutes and readings were noted for each cream 
formulation. 
 
Figure 4.  Brookfield viscometer (DV-II+) 
 
LV-4 spindle was fit near the shipping cap of viscometer and the formulations were placed on the 
guard leg, and the spindle was immersed into a glass vial. All the readings were taken in triplicate 
(n=3).  
Method of Analysis 
1. High Performance Liquid Chromatography (HPLC). 
2. Spectrophotometric analysis. 
High Performance Liquid Chromatography (HPLC) 
Analysis of voriconazole was done using a Waters HPLC system (Water 600 Controller, USA) 
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equipped with a 600-pump unit, a 717 plus auto sampler with an injection valve with a sample 
loop of 50 µl, and a 2487 dual absorbance UV detector. Peak area integration was performed using 
Breeze software. An isocratic HPLC method was developed for the quantification of voriconazole 
[6,7]. The method was validated for Sensitivity/Specificity, Linearity, Limit of detection (LOD), 
Limit of quantitation (LOQ), measuring range, accuracy and precision. Processing parameters for 
the HPLC method is described in table 3. 
Table 3. Processing parameters for the HPLC method. 
PARAMETERS DESCRIPTION 
Mobile phase 
A mixture of Acetonitrile and Water 
(50:50, v/v)  
Column 
A reversed-phase C18 column (25 cm × 4.6 mm i.d., particle 
size 5 µm) 
Detection wavelength 
The UV detector wavelength was set at 256 nm for 
voriconazole 
Flow rate 1.0 mL min−1 
Temperature 23 ± 1 ℃ 
Injection volume 25 µl 
Retention time 3.8 minutes 
Run time 9.00 minutes 
 
Spectrophotometric Analysis 
The analysis for voriconazole was carried out using a UV/VIS (Ultraviolet/Visible) 
spectrophotometer (Model-1800, Shimadzu, Japan) at the absorbance maximum (λmax) of 
voriconazole which was 256 nm using a quartz 96 well plate and against an appropriate blank. The 
solvents used were the same as the release media. The dilution was necessary in order to get UV 




Voriconazole Content Uniformity 
To determine the content uniformity of the creams, 10 mg samples were withdrawn from three 
different regions of the cream container [e.g. top, middle, bottom] and dissolved in 1 ml of DMSO 
(Dimethyl Sulfoxide). The mixtures were vortexed using multi-vortexer V-32 Grant-bio for 15 
minutes then subjected to sonication using FS60H (Fisher scientific) for 10 minutes. After 
sonication, the mixtures were centrifuged using AccuSpin Micro 17 Centrifuge (Fisher scientific) 
for 10 minutes and 100 µl of supernatant samples were collected and diluted up-to 1 ml with 
DMSO. The concentration of the samples was analyzed using HPLC. All samples were analyzed 
in triplicate. For analysis, a calibration curve of voriconazole ranging from 0.05 – 100 µg/ml was 





In-vitro Release Testing (IVRT) 
IVRT is well established for characterizing and evaluating the performance of semi-solid dosage 
forms [33]. IVRT can be a sensitive and discriminating method that is generally responsive to 
physicochemical changes in semisolid drug products. The IVRT pivotal study comparing the 
[drug] release rates of the products should be performed in a manner compatible with the general 
procedures and statistical analysis method specified in the United States Pharmacopeia (USP) 
General Chapter <1724>, Semisolid Drug Products – Performance Tests [8]. 
Drug Solubility Studies (Receptor Media Selection): 
It is important to determine the solubility and stability of a drug in the receptor media. Drug 
solubility studies are carried out to determine the ideal composition of the receptor media. To 
% 𝐷𝑟𝑢𝑔 Content =  
𝐴𝑐𝑡𝑢𝑎𝑙 𝐷𝑟𝑢𝑔
𝑇ℎeoretical 𝐷𝑟𝑢𝑔
 × 100 
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determine the saturation solubilities of voriconazole, 1 mg of voriconazole was weighed and mixed 
with 1 ml of various aqueous media with different compositions in 2 ml centrifuge tubes.  The 
aqueous media studied are described in Table 4.  The tubes were continuously shaken for 24 hours 
using a mechanical shaker.  Samples were collected and subjected to centrifugation at 13,000 RPM 
for 10-15 minutes. The resultant supernatants were collected and 10 times diluted with 80% 
methanol (since voriconazole is poorly soluble in water). 200 µl sample were transferred into 
HPLC vials for analysis. All the samples were analyzed in triplicate. A calibration curve of 
voriconazole ranging from 0.05 – 100 µg/ml was used for all analysis. 
 
Table 4. Various aqueous media with different concentrations for solubility studies. 
Samples number Media 
1 0.2 % Brij S20 
2 0.5 % Brij S20 
3 1 % Brij S20 
4 2 % Brij in 10 % PG  
5 0.2 % Brij C20 (AP) 
6 2 % PEG 400 
7 1 % T80 
8 1 % T20 
9 10 % PG 
10 PBS 
 
Drug-stability in Receiver Medium 
A standard stock solution ranging from 100 µg/ml-1 µg/ml was prepared. 100 µl of 100 µg/ml and 
100 µl of 10 µg/ml was taken and dissolved in 10 ml of receiver medium (2 % Brij S-20 in 10 % 
Propylene glycol) respectively. Both samples were vortexed for 5 minutes. From the mixture 500 
µl was collected and another 500 µl of Acetonitrile (a common solvent used for the analysis of 
voriconazole) was added and the samples were vortexed. Samples were refrigerated at – 20 ℃ 
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(noted as initial concentration/ 0 hr. concentration). Remaining samples were also refrigerated for 
48 hours. After 48 hours 500 µl was withdrawn and another 500 µl of Acetonitrile was added and 
the samples were vortexed. The concentration of the samples was analyzed using HPLC. All the 
samples were done in triplicate. For analysis calibration curve of voriconazole ranging from 0.1 – 
100 µg/ml was used. 
Membrane Inertness: 
Membrane inertness is done to see if there is any binding of drug to membrane. The membrane 
selected should offer free resistance to diffusion [8]. For the membrane inertness testing, three 
different concentration (500 µg/ml (High concentration), 250 µg/ml (Intermediate concentration) 
and 50 µg/ml (low concentration)) of standard stock solution of drug voriconazole was prepared.  
Stock solution was centrifuged for 10 minutes. Supernatant was collected from each concentration 
and added in the scintillation vials (All the samples were taken in triplicate, n=3). The selected 
membrane (table 5) was cut into small circular shape and 1 ml of sample was withdrawn from the 
centrifuge tube before soaking the membrane. The membrane was soaked in the scintillation tube 
and kept aside for 24 hours. After 24 hours 200 µl of sample was withdrawn from each centrifuge 
tubes and the before and after samples were analyzed using HPLC. 
Table 5. Membrane for IVRT. 
Membrane for IVRT 
Membrane Nylon 
Pore size 0.22 µm 




In-vitro drug release test 
Vertical Franz diffusion cells with a volume of 5 ml (contact area: 0.64 cm2, Logan Instruments 
Corp) were used to determine the in vitro drug release of the voriconazole from the formulations 
(Fig. 5).  
   
Figure 5. Franz diffusion cell. 
 
Franz-cells were thoroughly washed with the buffer prior to starting release study. Donor cells and 
rubber rings were washed with 50 % methanol and 50 % water and kept for sonication for 10 
minutes. Dried donor cells and rubber rings were used for release study. Franz cells were connected 
to the consoler and 5 ml of the receiver media was added. Stir bar was placed in each of the Franz 
cells and turned on the consoler. Consoler was connected to the water jacket and temperature was 




following the addition of the release media. Then the donor chambers were mounted on the 
membranes and clamped tightly. 300 mg samples of the creams were loaded into the donor 
chambers. The stirring speed of the Franz diffusion cells was set at 600 rpm. At pre-determined 
time intervals (0, 1, 2, 3, 4, 5 and 6 hours), aliquots of 0.3 ml of the media were withdrawn from 
the receptor chambers and replenished with fresh media. Processing parameter for IVRT is 
described in table 6. Voriconazole was estimated spectrophotometrically at 256 nm. UV spectrum 
of voriconazole was observed for voriconazole transported through the membrane at different time 
period. 
Table 6. IVRT parameters. 
Illustrative IVRT parameters  
Parameter Description 
Diffusion cell 5-station Franz diffusion cell 
Weight of sample 300 mg of creams 
Membrane Nylon membrane, 0.47 mm diameter and 0.22 µm 
Receptor media 2 % Brij S20 in 10 % propylene glycol 
Temperature 32± 0.5 ℃ 
Sampling aliquot 300 µl 
Sampling time 0, 1, 2, 3, 4, 5 and 6 hours 
 
In-vitro Permeation Testing (IVPT) 
Drug permeation through skin under in vitro conditions can be used to predict percutaneous 
absorption in humans [10]. For the studies a fresh human cadaver skin (New York fire fighters skin 
bank) stored in glycerin at a temperature of -20 ℃ was used.  Prior to starting the experiment, the 
skin was taken out and kept in phosphate buffer solution (PBS) in order to wash the glycerin from 
the skin.  
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The in-vitro skin permeation study was performed using Franz diffusion cells with an effective 
diffusion area of 0.64 cm2. A human cadaver skin was sandwiched between the donor and receiver 
media with the subcutaneous (SC) side facing the donor compartment because of uniform diffusion 
studies. The receiver compartment was filled with 5 ml of receptor media (2 % Brij S-20 in 10 % 
propylene glycol) and temperature was maintained at 32 ± 0.5 °C. The dose for finite dose study 
was 10 mg /cm2. In the finite dose regime, only a limited amount of the donor formulation is 
applied to the skin surface. The application of a finite dose supposedly best resembles the in vivo 
situation when applying e.g., a cream. The finite dose studies would be close to clinically relevant 
dose and   it would reveal the way the formulation would behave and perform in the clinical 
conditions. During the IVPT studies, at pre-determined time points (0, 4, 8, 12, 18, 24, 30 and 36 
hours), aliquots of 0.2 ml of the media were withdrawn from the receptor chambers and replenished 
with fresh media. The amount of voriconazole in these samples was quantified using HPLC.  In 
Finite dose study, the average flux was calculated and plotted to determine the maximum flux (J 




CHAPTER III: RESULTS AND DISCUSSION 
Screening of Excipients 
Fourier Transform Infrared Spectroscopy (FT-IR) 
The FT-IR spectra of the voriconazole, excipients and formulations were analysed to determine 
the physical (H-bonding) or chemical interactions between API and Excipients.  The voriconazole 
powder exhibited absorption peaks at 3191 cm-1 corresponding to the stretching vibrations of OH. 
The bands at 3000–2850, 1600–1400, and 1360–1250 cm-1 were assigned to the alkane CH, C = 
C aromatic and aryl C-N stretches [26][27][28] as shown in the figure 10, 11, 12 and 13. The 
formulations showed no major shifting of any functional peaks between the spectra of drug and 
excipients alone. The characteristics peaks of drug in the formulations were diminished when 
compared with pure drug peak at same wave number (3191 cm−1). The spectrum shows that there 












Figure 8.  FT-IR of voriconazole, excipients and F10A. 
 
 
Figure 9. FT-IR of voriconazole, excipients and F10B. 
Preparation and Optimization of Oil/PEG Creams 
The preliminary screening of the formulations was done based on the stability and the 
consistency of the formulations. In order to determine the stability, a three cycles of accelerated 
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stability study was carried out using “freeze thaw stability” and later the formulations were 
visually inspected for the phase separation and the consistency. 
 
Figure 10. Freeze thaw stability cycle. 
 
Table 7. Compositions containing PEG 1450 and PEG 400, Subjected for Freeze thaw cycle. 
Ingredients 
Percentage (%) of compositions 
F1 F2 F3 F4 F5 F6 F7 F8 
PEG 1450 15 15 20 20 30 30 50 50 
PEG 400 85 85 80 80 70 70 50 50 
Propylene Glycol 8 8 8 8 8 8 8 8 
API 1 1 1 1 1 1 1 1 
Labrafil M 1944 
CS*/Light mineral 
oil** 
20* 20** 20* 20** 20* 20** 20* 20** 
Tefose 63 5 5 5 5 5 5 5 5 
 
Table 8. Compositions containing PEG 2000 and PEG 400, Subjected for Freeze thaw cycle. 
Ingredients 
Percentage (%) of compositions 
F9 F10 F11 F12 F13 F14 F15 F16 
PEG 2000 15 15 20 20 30 30 50 50 
PEG 400 85 85 80 80 70 70 50 50 
Propylene Glycol 8 8 8 8 8 8 8 8 
API 1 1 1 1 1 1 1 1 
Labrafil M 1944 
CS*/Light mineral 
oil** 
20* 20** 20* 20** 20* 20** 20* 20** 
Tefose 63 5 5 5 5 5 5 5 5 
 
Table 9. Compositions containing PEG 3350 and PEG 400, Subjected for Freeze thaw cycle. 
Ingredients 
Percentage (%) of compositions 
F17 F18 F19 F20 F21 F22 F23 F24 
PEG 3350 15 15 20 20 30 30 50 50 
PEG 400 85 85 80 80 70 70 50 50 
Propylene Glycol 8 8 8 8 8 8 8 8 
API 1 1 1 1 1 1 1 1 
Labrafil M 1944 
CS*/Light mineral oil** 
20* 20** 20* 20** 20* 20** 20* 20** 
24 h at 
Room 
Temperature
24 h at -20 
°C
24 h at 
Room 
Temperature
24 h at 45 
°C





Tefose 63 5 5 5 5 5 5 5 5 
 
Table 10. Compositions containing PEG 4500 and PEG 400, Subjected for Freeze thaw cycle. 
Ingredients 
Percentage (%) of compositions 
F25 F26 F27 F28 F29 F30 F31 F32 
PEG 4500 15 15 20 20 30 30 50 50 
PEG 400 85 85 80 80 70 70 50 50 
Propylene Glycol 8 8 8 8 8 8 8 8 
API 1 1 1 1 1 1 1 1 
Labrafil M 1944 
CS*/Light mineral 
oil** 
20* 20** 20* 20** 20* 20** 20* 20** 
Tefose 63 5 5 5 5 5 5 5 5 
* Formulation containing Labrafil M 1944 CS in oil phase. 
** Formulation containing Light mineral oil in oil phase. 
Composition – 75 % aqueous phase (Solid PEG, Liquid PEG, Propylene glycol and API) and 25 
% oil phase (Labrafil M 1944 CS/ Light mineral oil and Tefose 63). 
All the formulations (F1-F8) or the creams which had combinations of solid PEG (PEG 1450) and 
Liquid PEG (PEG 400), showed phase separation after accelerated stability studies. Hence 
formulations having combinations of PEG 1450 and PEG 400 were not selected for the further 
studies. Formulations (F17-F24) or the creams which had combinations of solid PEG (PEG 3350) 
and Liquid PEG (PEG 400) and the formulations (F24-F32) or the creams which had combinations 
of solid PEG (PEG 4500) and Liquid PEG (PEG 400), had a very thick consistency. Hence the 
formulations having combinations of PEG 3350, 4500 and PEG 400 were not selected for the 
further studies either. Formulations (F13-F16) had higher percentage of solid PEG (PEG 2000) in 
the compositions hence the consistency of the formulation was thick and was unable to transfer 
the formulations into container because of the flakes like consistency. Hence formulations F13-
F16 were eliminated. Formulations (F9-F12) had an acceptable consistency and were considered 
for further characterization. Microscopic images of the formulations (F11 and F12) showed a 
distorted globule and the formulations (F9 and F10) showed a clear globule (figure.9 and 10). 
Hence the formulations (F9 and F10) were selected for the further manufacturing and 
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characterizations.     
   
Figure 11. Microscopic images of formulation F11 and F12. 
  
Figure 12. Microscopic images of formulation F9 and F10. 
 
Preparation of Selected Formulations Using a Twin-Screw Processor 
 
The base formulations F9 and F10 were selected for the manufacturing process after screening 
studies. 
Hot melt extrusion (HME): Selected four formulations (F9A, F9B (1 % API) and F10A, F10B 





subjected to further characterizations.  
  
Figure 13. Representation of the Hot melt extrusion setup. 
 
Differential scanning calorimetry (DSC) 
DSC was done to determine if voriconazole remains in the amorphous form in the formulation or 
to know if it is soluble in the formulation (figure.14, 15, 16 and 17). The thermogram obtained 
showed that the voriconazole had one endothermic peak at 127 ℃, which shows that voriconazole 
exists only in one polymorphic form. Thermogram of the prepared creams, F10B showed complete 
disappearance of the drug peak which suggests that either all the drug has been dissolved in the 
base or the increase in temperature during DSC experimentation has solubilized the drug in the 
base. Thermogram of the creams (F9A, F9B and F10A) showed very low intensity peaks, which 
indicate that the crystalline peak of voriconazole either disappeared or shifted to lower 
temperatures. This observation shows that the conversion of voriconazole from crystalline form to 




Figure 14. DSC of pure components and F9A. 
 




Figure 16. DSC of pure components and F10A. 
 
 
Figure 17. DSC of pure components and F10B. 
 
pH Measurements.   
According to the pH/ partition theory, the unionized drug has more ability to permeate compared 
to the ionized form of the drug. pH of the skin is considered to be around 5.5 and hence acceptable 
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semisolid formulations should have a pH ranging from 5.5-7.0 to be compatible with the skin. 
Voriconazole is a weak base (pKa 1.76) [37], the drug remains in the ionized state in the formulation 
with pH above > 6. It was found that the pH of the topical products can change post application 
on the skin due to homeostasis [13] [14]. The pH of all the prepared formulations did not differ 
significantly. 
 







Solvent Activity (aW) Measurements 
Solvent activity (aw) is simply defined as the ratio of the vapor pressure of pure water (100% 
equilibrium relative humidity) over the vapor pressure of the sample. Solvent activity gives a clear 
understanding about the formulations and its potential for microbial contamination. Solvent 
activity of the prepared formulations was found to be low as described in table 12, however the 
formulations did not have water in the compositions. Hence it can be concluded that the solvent 
activity of the prepared formulations is accurate, since most of the creams are either Oil/Water and 
Water/Oil creams which will have higher solvent activity. The formulations with low solvent 
activity have significant influence on hydrodynamics of skin, and this was associated with 






Table 12. Solvent activity (aw) of the manufactured formulations. 







It is essential to determine the viscosity of the formulations as it determines the free flow of the 
formulation from the container ensuring the ease of administration. A viscosity range of (10 – 60) 
104 cP is most common for topical formulations i.e., lotions, gels and creams [24][25]. Viscosity of 
all the formulations were found well within the range. 
 
Table 13. Viscosity measurement of the manufactured formulations. 
Samples Viscosity (cP) 
F9A (24.13±0.5033) X 104 
F9B (35.40±1.7088) X 104 
F10A (27.53±1.3317) X 104 
F10B (34.33±3.0022) X 104 
 
Drug Content Uniformity 
As mentioned earlier, uniform mixing of the API with cream base is one of the challenging tasks 
in manufacturing of topical semi-solids. Uniformity of drug content indicates the efficiency of 
mixing process and the relative standard deviation (RSD) of the drug content is a good indication 
of the uniformity of the creams. In this study, we found that the drug content of all the prepared 
creams were within the acceptable range of >90%, the limit set by the USP [34]. In addition, the 
RSD of the drug concentration calculated based on samples taken from different regions of the 
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creams was less than 3.5%, indicating adequate uniformity of the drug particles in the creams 
[21][29].  
 
Table 14. Drug content uniformity of the manufactured formulations. 






In-vitro Release Testing (IVRT) 
Drug Solubility Studies (Receptor media selection): 
Prior to starting the IVRT, it is important to select the suitable receptor media which will allow the 
drug to maintain sufficient sink condition. Screening of different aqueous media with varying 
concentrations was done before selecting the suitable receptor media for the drug voriconazole 
[18][19].  
 
Table 15. Solubility studies results of various aqueous media with different concentrations. 
Samples number Media Solubility (µg/ml) 
1 0.2 % Brij S20 648.16 
2 0.5 % Brij S20 793.68 
3 1 % Brij S20 1033.73 
4 2 % Brij S20 in 10 % PG  1369.02 
5 0.2 % Brij C20 (AP) 570.16 
6 2 % PEG 400 488.90 
7 1 % T80 694.19 
8 1 % T20 789.44 
9 10 % PG 655.75 
10 PBS 477.22 
 
As shown in Table 15, voriconazole had a good solubility in 0.5 % BrijTM S-20, 1 % BrijTM S-20, 
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2 % w/v BrijTM S-20 in 10 % propylene glycol and 1 % T20. But compared to other release medias, 
voriconazole had the highest saturation solubility in 2 % w/v BrijTM S-20 in 10 % propylene glycol. 
Hence 2 % w/v BrijTM S-20 in 10 % propylene glycol was selected as the release medium as it 
completely solubilized voriconazole and had the maximum solubility for voriconazole with respect 
to other release medias with different surfactants solutions. 
Drug-Stability in Receiver Medium 
A drug-degradation study is carried out to find if the drug is degraded in the receiver medium. The 
degradation study was carried out at different concentrations (100 µg/ml and 10 µg/ml) of 
voriconazole in the receiver medium. As shown in Table 16, voriconazole was not degraded in the 
receiver medium. 
 
Table 16. Drug stability in receiver medium. 
Sample Stability (%) 
100 µg/ml 98.69 
10 µg/ml 111.08 
 
Membrane Inertness: 
From the literature search it was found that nylon membrane, pore size 0.22 µm and diameter of 
0.47 mm had previously been used in a release study of voriconazole [23] formulations.   However, 
it is important to know if there is any resistance to diffusion by the API caused by the membrane 
and if release is proportional to the concentration of the drug in the formulation.  A membrane 
inertness study was done by using different concentrations of a standard voriconazole stock 
solution. The samples were refrigerated at -20 ℃ for 24 hours. Before and after concentration of 
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drug was analyzed using HPLC. For analysis calibration curve ranging from 0.1 µg/ml to 100 
µg/ml was used. Nylon membrane, pore size 0.22 µm and diameter of 0.47 mm membrane was 
selected because of its inertness to the API. There was negligible absorption of API on the 
membrane before and after exposure to the drug solution. Hence it is concluded that the membrane 
is not acting as a rate controlling barrier and the release is absolutely attributable to formulation 
properties. 
 
Table 17. Membrane inertness study results. 
Samples % Adsorbed to membrane 
High concentration (500 µg/ml) 0.86 
Medium concentration (250 µg/ml) 0.70 
Low concentration (50 µg/ml) 0.10 
 
In-vitro Drug Release Test 
In-vitro release test was carried out using Franz diffusion cell (FDC), most commonly used in 
topical semisolid formulations [33]. For the release study, 2 % w/v BrijTM S-20 in 10 % propylene 
glycol (PG) was used as the receiver media and a nylon membrane (pore size 0.22 µm and diameter 
of 0.47 mm) was used as the diffusion membrane. As shown in figure. 18. All of the four oil/PEG 
cream formulations (F9A, F9B, F10A and F10B) prepared by the hot melt extrusion process 
followed Higuchi’s release profile. Hence it can be concluded that hot melt extrusion can be used 
as continuous process method of preparing an emulsion with the potential of enhancing the 
solubility of API in the formulation and providing proper distribution of the API throughout the 
composition. Comparing the four formulations, F10A (slope 3539.62) and F10B (slope 6854.44) 
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had a higher rate of release profile compared to F9A (slope 1436.55) and F9B (slope 1966.08) 
(Figure 18).   
 
Figure 18. In-vitro drug release profile of the formulations. 
In-vitro Permeation Testing (IVPT) 
After in-vitro release test, formulations were subjected to permeation studies. However, for the 
permeation studies formulations only the formulations which had 3 % voriconazole (F10A and 
F10B) were selected. Since the water activity of these formulations was low, a low permeation 
profile was expected. From the literature search it was found that, camphor-menthol (1:1) had 
previously been used as a permeation enhancer for the formulations having voriconazole [23]. 
Transcutol P at a low concentration was also explored as a permeation enhancer in the 
formulations. Transcutol P, is an excellent solvent and powerful solubilizer and penetration 
enhancer for topical formulations [35]. It is safe to use and has low irritancy inferred by numerous 
toxicological studies and precedence of use in approved topical medicines [35]. As per the FDA’s 
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been used in FDA approved drug products [36]. In the current study only 7.5% w/v of Transcutol P 
was used as permeation enhancer. For the permeation studies, formulations (F10A2 and F10B2) 
containing 7.5% w/v camphor-menthol (1:1) were used as positive control, formulations without 
permeation enhancer was used as negative control, and permeation enhancer activity of 
formulations (F10A1 and F10B1) containing 7.5% w/v Transcutol P was tested. A finite dose 
permeation study was carried out [22][23]. 
The finite dose permeation flux versus time profile followed a typical up and down curve in all the 
formulations. The area under the curve (AUC) of the formulations (F10B1 and F10B2), had five-
fold increment compared to the formulations without permeation enhancer; and formulations 
(F10A1 and F10A2), had three-fold increment compared to the formulations without permeation 
enhancer. The Jmax values of the formulations shown in Table16. Formulation with permeation 
enhancer Transcutol P (F10B1) showed the highest flux/ Jmax. Formulation (F10B1) showed nine-
fold increment compared to the formulations without permeation enhancer and one-fold increment 





Table 18. Comparison of AUC (µg/cm2) and Jmax (µg/cm2/h). 
Samples AUC (µg/cm2) Flux (µg/cm2/h) Tmax (h) 
Cream without 
permeation enhancer 
(Light mineral oil) 
0.699±0.763 0.182±0.098 30±6.0000 
Cream without 
permeation enhancer 
(Labrafil M 1944 CS) 
0.535±0.304 0.115±0.075 22±3.4641 
F10A1 1.315±1.038 0.355±0.264 8.67±8.0829 
F10B1 2.550±0.789 0.909±0.302 4±0.0000 
F10A2 1.562±1.005 0.554±0.393 6.67±4.6188 






































CHAPTER IV: CONCLUSION 
Oil/PEG creams of voriconazole were successfully developed in order to overcome the 
degradations problem of voriconazole in aqueous base formulations (i.e., Oil/Water or Water/Oil). 
Stable voriconazole topical creams formulations was successfully developed and evaluated. Hot-
melt extrusion was used in the manufacturing of voriconazole creams; suggesting the feasibility 
of using hot melt extrusion as a continuous manufacturing tool for semi-solid formulations. 
Further, it was found that transcutol P at a lower concentration can be used as permeation 
enhancers over camphor-menthol (1:1). From the results it was clear that the permeation profile of 
the formulations with permeation enhancer, transcutol P was much better than the permeation 
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